Generally, absolute rates of serious ocular adverse events are low (≤ 2.1%) and most discordant judgements of anti-VEGF drugs focus on their systemic safety.[17] [20] In addition, the frequency of very rare procedure-related events, such as endophthalmitis, is better studied in large observational series or registries rather that in RCTs.[21]. Here, VEGFA is linked to endophthalmitis.